THE Therapeutic Goods Administration (TGA) has updated the indication for Ultibro Breezhaler (110/50 indacaterol maleate/glycopyrronium bromide).
This is the first long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination therapy approved to reduce exacerbations of chronic obstructive pulmonary disease (COPD) in patients with a history of exacerbations.
Professor Peter Frith from Flinders Medical Centre in Adelaide said the "the ability to prescribe a LABA/LAMA combination to high-risk COPD patients should lead to a reduction in the use of inhaled steroids" - CLICK HERE for the PI.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Sep 17